News

Dystrogen Gene Therapies

Dystrogen Gene Therapies is a life sciences company focused on the development of therapies for rare genetic neurodegenerative disorders. Our currently most advanced therapeutic candidate is for Huntington’s Disease (HD) and has produced a series of highly promising pre-clinical data.


Dystrogen Therapeutics

Dystrogen Therapeutics is a clinical-stage chimeric cell therapy company focusing on rare diseases. The company is currently testing in humans the Dystrophic Expressing Chimeric (DEC) cell therapy for Duchenne Muscular Dystrophy – a terminal illness that affects young boys and lead the gradually worsening dysfunction of the muscular system.


Kardiolytics

Kardiolytics has the goal to make advanced, highly accurate diagnostics of the heart – inexpensive and widely available, including the parts of the world that currently have limited access to advanced medical diagnostics.  The Kardiolytics technology uses Artificial Intelligence to derive from inexpensive and widely available CT scans of the heart – crucial diagnostic information about narrowing of blood vessels, that normally can be obtained only by applying complex, expensive, and highly invasive procedures that involve inserting probes into the heart.